Methode Electronics, Inc. (MEI) Forms $40.00 Double Bottom; Aveo Pharmaceuticals (AVEO)’s Sentiment Is 1.32

December 13, 2017 - By Louis Casey

Methode Electronics, Inc. (MEI) formed double bottom with $38.40 target or 4.00% below today’s $40.00 share price. Methode Electronics, Inc. (MEI) has $1.53 billion valuation. The stock decreased 2.08% or $0.85 during the last trading session, reaching $40. About 337,126 shares traded or 52.29% up from the average. Methode Electronics, Inc. (NYSE:MEI) has risen 40.98% since December 13, 2016 and is uptrending. It has outperformed by 24.28% the S&P500.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $456.21 million. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

Analysts await Methode Electronics, Inc. (NYSE:MEI) to report earnings on December, 14. They expect $0.63 earnings per share, down 4.55% or $0.03 from last year’s $0.66 per share. MEI’s profit will be $24.05M for 15.87 P/E if the $0.63 EPS becomes a reality. After $0.60 actual earnings per share reported by Methode Electronics, Inc. for the previous quarter, Wall Street now forecasts 5.00% EPS growth.

Among 3 analysts covering Methode Electronics (NYSE:MEI), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Methode Electronics has $55 highest and $37 lowest target. $44.33’s average target is 10.83% above currents $40 stock price. Methode Electronics had 11 analyst reports since September 4, 2015 according to SRatingsIntel. The firm has “Buy” rating by Robert W. Baird given on Friday, June 23. The rating was maintained by Robert W. Baird with “Buy” on Thursday, September 21. As per Friday, September 4, the company rating was upgraded by Craig Hallum. The stock of Methode Electronics, Inc. (NYSE:MEI) has “Outperform” rating given on Friday, December 9 by FBR Capital. The stock of Methode Electronics, Inc. (NYSE:MEI) earned “Buy” rating by FBR Capital on Tuesday, December 5. As per Friday, June 24, the company rating was upgraded by Robert W. Baird. The stock of Methode Electronics, Inc. (NYSE:MEI) has “Outperform” rating given on Friday, March 3 by FBR Capital. Robert W. Baird maintained it with “Buy” rating and $46.0 target in Monday, October 16 report. The rating was downgraded by Craig Hallum on Friday, September 2 to “Hold”. The stock of Methode Electronics, Inc. (NYSE:MEI) earned “Buy” rating by Robert W. Baird on Friday, December 8.

The stock decreased 1.00% or $0.03 during the last trading session, reaching $2.97. About 975,785 shares traded. AVEO Pharmaceuticals, Inc. (AVEO) has declined 16.67% since December 13, 2016 and is downtrending. It has underperformed by 33.37% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: